Article info

Download PDFPDF
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody

Authors

  1. Correspondence to Professors Chunde Bao and Qiang Guo, Rhematology Department of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.145, Shangdong (c) Road, 200001, Shanghai, China; baochunde_1678{at}126.com and marquisjerry{at}126.com
View Full Text

Citation

Zou J, Li T, Huang X, et al
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody

Publication history

  • Received January 23, 2014
  • Revised March 16, 2014
  • Accepted March 22, 2014
  • First published April 16, 2014.
Online issue publication 
July 03, 2014

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.